Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
A new study shows that recognizing the differences in the population composition, connectedness and distribution, as well as inter-individual differences in immunity, susceptibility and infectivity, are crucial to estimating the herd immunity attained as a result of natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) more accurately.
rust in public institutions is linked to fewer COVID-19 deaths, but trust and belonging to groups is associated with more deaths, according to a wide-ranging, McGill-led study of 30-day COVID-19 mortality rates in 84 countries.
Scientists have spotted a once-in-a-century climate anomaly during World War I that likely increased mortality during the war and the influenza pandemic in the years that followed.
Due to continual improvements in transportation technology, people travel more extensively than ever before. Although this strengthened connection between faraway countries comes with many benefits, it also poses a serious threat to disease control and prevention.
A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.
Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good.
Millions of Americans are counting on a COVID-19 vaccine to curb the global pandemic and return life to normal.
A new study published on the preprint server bioRxiv* in August 2020 shows that the man-made compound silicon nitride, which is used in medical implants and high mechanical performance engineering applications, is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at varying concentrations without causing cell cytotoxicity. This finding should be investigated to develop disinfectants to clear the virus from surfaces, preventing its spread.
Now, a team of researchers at Kansas State University aimed to determine if pigs are potential carriers of SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19).
A recent study published in the journal JAMA Network Open reveals that the excess death toll observed during the initial period of coronavirus disease 2019 (COVID-19) pandemic in New York City is comparable to that observed during the peak of the H1N1 influenza pandemic in 1918.
The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.
In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.
The coronavirus pandemic, which has now infected nearly 19 million and killed more than 712,000 people, most likely originated from bats. Just like other coronavirus outbreaks in the past, a spill-over event or zoonosis caused the viruses to jump from animals to humans.
Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.
Now, a new study published on the preprint server medRxiv in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in hospitalized COVID-19 patients by an astonishing 57%. This adds evidence for the use of convalescent plasma in the treatment of high-risk patients.
Now, a new study published on the preprint server bioRxiv in July 2020 reports the development of a human distal lung culture system that can be functionally tested. This will help not only to understand how this infection produces disease but also to test the proliferative capacity of the stem cells in this part of the body.
Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.
According to new research, the failure to protect tropical rain forests has cost trillions of dollars stemming from the coronavirus pandemic, which has wreaked economic havoc and caused historic levels of unemployment in the United States and around the world.
A vaccine additive known as an adjuvant can enhance responses to a vaccine containing the exotic avian flu virus H5N1, so that both rookie and veteran elements of the immune response are strengthened, according to results from an Emory Vaccine Center study.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.